Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as
the safety and tolerability of oral nimodipine in progranulin mutation carriers in
preparation for longer term efficacy studies in patients with frontotemporal dementia due to
progranulin gene mutations.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
The Bluefield Project The Bluefield Project to Cure Frontotemporal Dementia